Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Beckerman will represent Elixinol’s position in hemp industry’s dynamic U.S. regulatory and advocacy environment DENVER , Jan 03, 2019 — Elixinol, a wholly owned subsidiary of Elixinol Global (EXL) (asx:EXL) announces Joy Beckerman’s appointment to Elixinol’s […]
Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]
VANCOUVER, Washington and NEW YORK, Dec 17, 2019 – In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
